PTGS2 and neoplasm: The low-PTGS2 group enjoyed a higher percentage of M1 macrophages, with a higher tumor mutation burden, and the mutation of the most significantly different mutated gene, TEMN2, seemed to contribute to the efficacy of immunotherapy, for having a potential correlation with high neoantigens and PD-L1 high-expression.